ブライトパス・バイオ株式会社 Hisse Grafiği

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer peptide vaccines, which constitute one form of cancer immunotherapy. It has developed ITK-1, a cancer peptide vaccine, which is in phase III clinical study to treat prostate cancer; and GRN-1201 that is in phase II clinical study for the treatment of non-small cell lung cancer, as well as in phase I clinical study to treat melanoma. The company’s products include GRN-1301, a drug resistant tumor-derived neo-antigen for the treatment of non-small cell lung cancer; and iPS-NKT, an induced pluripotent stem cell derived regenerated NKT cell therapy. BrightPath Biotherapeutics was founded by Ito Kyogo on May 8, 2003 and is headquartered in Tokyo, Japan.